Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00436787
First received: February 16, 2007
Last updated: May 15, 2008
Last verified: May 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2007
  Estimated Primary Completion Date: No date given